A New Computer-Modelling Tool to Improve Psoriasis Management and Treatment Outcomes

LEO Pharma has unveiled a new weapon in its long-running campaign to improve psoriasis management and treatment outcomes. However, the weapon is not a new drug but a ground-breaking computer-modelling tool, designed to help those involved in the assessment, planning and provision of psoriasis treatment in primary care to balance optimum outcomes with the growing need for cost control.

Called 'Psoriasis and Me', the new computerised resource simulates the impact (over two years) of the use of a range of topical psoriasis therapies on patient outcomes and costs in a given primary care setting.

Co-developed in the UK by LEO Pharma and specialist health economics and outcomes research company Amygdala Ltd, 'Psoriasis and Me' has been piloted with English service providers for the past 11 months and is already endorsed by the UK’s National Association of Primary Care (NAPC).

The pilot has not only revealed the extent to which providers in England are unaware of the sizeable sums being spent on psoriasis but also the very real prospect of significant savings which could run into millions of pounds if replicated across the UK.

"Health economics is an increasingly important factor in service redesign but it is often seen as a cold discipline that works against patient needs; 'Psoriasis and Me' demonstrates that this doesn't have to be the case," said Peter Jackson, Commercial Development Manager for LEO UK.

"The programme has already shown that as a result of more effective prescribing for psoriasis in an English primary care population of, say, 250,000, yearly savings could be as high as £277,000. If you extrapolate that to the UK population as a whole (c60million), the potential annual saving could be as much as £66million."

The programme has also received extremely positive feedback from clinicians who have seen it in operation. Keith Freeman, a UK Consultant Dermatologist with dual responsibility for services in a primary care trust and a foundation hospital trust, sees the programme as a very welcome and valuable aid for local decision making. "The priority for service commissioners in treating psoriasis is to achieve the best pathways of care - to make sure that the right patients are being treated in the right place at the right time for the best possible outcomes. Treating effectively in primary care is better for the patient and also means secondary care resources can be focused on the most appropriate cases. Tools like this are the way forward to help clinicians review services, optimise care and keep better control of costs."

'Psoriasis and Me' works by comparing specific local data inputs - such as population size, waiting times for referrals to secondary care and the types and costs of treatments currently in use - to stored country-specific information and the Psoriasis Area and Severity Index (PASI 75). It then generates a report which calculates the optimum financial savings that could be made in a service redesign which would also improve patient outcomes using the most effective treatments.

"For decades, LEO Pharma has been at the forefront of challenging psoriasis," said Kristian Hart-Hansen, LEO Pharma's Manager of Corporate Pricing and Health Economics. "To date this has been with treatments but now that most countries insist on some form of Health Technology Assessment (HTA) to demonstrate cost effectiveness, we want to add value to the process. The idea for 'Psoriasis and Me' came from an HTA submission and, after the success of the UK pilot, its potential to reinforce our challenge to this life-affecting disease is very clear."

'Psoriasis and Me' is now under development for use in a number of Northern European countries and LEO Pharma plans to roll out the programme over the next two years.

About LEO Pharma
LEO Pharma is an independent research based company with headquarters in Ballerup, Denmark. LEO Pharma is 100% owned by the LEO Foundation and is a globally leading company within Dermatology and Critical Care. LEO Pharma has a strong focus on developing, manufacturing and marketing safe and efficacious drugs for treating psoriasis and other skin diseases as well as thromboembolic disorders. For further information, please visit www.leo-pharma.com.

Source: World Pharma News

Most Popular Now

AI Catches One-Third of Interval Breast …

An AI algorithm for breast cancer screening has potential to enhance the performance of digital breast tomosynthesis (DBT), reducing interval cancers by up to one-third, according to a study published...

Researchers Create 'Virtual Scienti…

There may be a new artificial intelligence-driven tool to turbocharge scientific discovery: virtual labs. Modeled after a well-established Stanford School of Medicine research group, the virtual lab is complete with an...

From WebMD to AI Chatbots: How Innovatio…

A new research article published in the Journal of Participatory Medicine unveils how successive waves of digital technology innovation have empowered patients, fostering a more collaborative and responsive health care...

AI also Assesses Dutch Mammograms Better…

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by...

RSNA AI Challenge Models can Independent…

Algorithms submitted for an AI Challenge hosted by the Radiological Society of North America (RSNA) have shown excellent performance for detecting breast cancers on mammography images, increasing screening sensitivity while...

AI could Help Emergency Rooms Predict Ad…

Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study by the...

Head-to-Head Against AI, Pharmacy Studen…

Students pursuing a Doctor of Pharmacy degree routinely take - and pass - rigorous exams to prove competency in several areas. Can ChatGPT accurately answer the same questions? A new...

NHS Active 10 Walking Tracker Users are …

Users of the NHS Active 10 app, designed to encourage people to become more active, immediately increased their amount of brisk and non-brisk walking upon using the app, according to...

New AI Tool Illuminates "Dark Side…

Proteins sustain life as we know it, serving many important structural and functional roles throughout the body. But these large molecules have cast a long shadow over a smaller subclass...

The Human Touch of Doctors will Still be…

AI-based medicine will revolutionise care including for Alzheimer’s and diabetes, predicts a technology expert, but it must be accessible to all patients. Healing with Artificial Intelligence, written by technology expert Daniele...

Deep Learning-Based Model Enables Fast a…

Stroke is the second leading cause of death globally. Ischemic stroke, strongly linked to atherosclerotic plaques, requires accurate plaque and vessel wall segmentation and quantification for definitive diagnosis. However, conventional...

Brain Imaging may Identify Patients Like…

By understanding differences in how people’s brains are wired, clinicians may be able to predict who would benefit from a self-guided anxiety care app, according to a new analysis from...